Trial Profile

Characterization of the Toll-like Receptor 7-agonist Imiquimod 3.75% as a New Surrogate Model of Itch

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 26 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Imiquimod (Primary) ; Doxepin
Indications Actinic keratosis; Basal cell cancer; Genital warts; Herpes simplex virus infections
Focus Pharmacodynamics

Most Recent Events

13 Jan 2021 Planned initiation date changed from 1 Sep 2019 to 1 Nov 2019.
13 Jan 2021 Status changed from not yet recruiting to withdrawn prior to enrolment as Imiquimod 3.75% was ineffective.
22 Jan 2020 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com